Tsai, Yao-Tsung
Li, Chih-Yi
Huang, Yen-Hua http://orcid.org/0000-0001-6020-9998
Chang, Te-Sheng
Lin, Chung-Yen http://orcid.org/0000-0002-4733-9488
Chuang, Chia-Hsien http://orcid.org/0000-0002-3639-4684
Wang, Chih-Yang http://orcid.org/0000-0002-4137-5074
Anuraga, Gangga
Chang, Tzu-Hao http://orcid.org/0000-0001-7011-3754
Shih, Tsung-Chieh http://orcid.org/0000-0001-7992-1504
Lin, Zu-Yau
Chen, Yuh-Ling http://orcid.org/0000-0001-7760-5954
Chung, Ivy http://orcid.org/0000-0003-2840-8123
Lee, Kuen-Haur
Chang, Che-Chang http://orcid.org/0000-0001-8080-2094
Sung, Shian-Ying
Yang, Kai-Huei
Tsui, Wan-Lin
Yap, Chee-Voon
Wu, Ming-Heng http://orcid.org/0000-0002-5740-9144
Funding for this research was provided by:
Ministry of Science and Technology, Taiwan (MOST 109-2314-B-038-134, MOST 110-2320-B-038-018, and MOST 110-2314-B-038-133)
Ministry of Education (Ministry of Education, Republic of China (DP2-110-21121-01-T-03-01, DP2-109-21121-01-T-03-01, DP2-108-21121-01-T-02-04, and DP2-107-21121-T-02)
National Health Research Institutes (NHRI-EX109-10918BI and NHRI-EX110-10918BI)
Article History
Received: 20 August 2021
Revised: 28 March 2022
Accepted: 31 March 2022
First Online: 22 April 2022
Competing interests
: TCS is an inventor of Galectin-1 inhibitor LLS30, and a scientific founder of Kibio Inc. which plans to develop the LLS30.